Skip to main content

Pharma News

 

Clinical courses

 

Clinical research courses

Get the latest news from world and India’s leading pharmaceutical companies Pharma Industry, pharmaceutical marketing, generic drugs, and Complete news for Pharmacy and Life Sciences professionals.

  • Study Sets New Standard for Graft-Versus-Host Disease Prevention After Stem Cell Transplant

    Clinicians have a new standard for graft-versus-host disease (GVHD) prevention after allogeneic hematopoietic stem cell transplantation, according to results from a phase III study published June 22 in the New England Journal of Medicine. The new standard is more effective at preventing GVHD and came with less side effects, compared with the current gold standard.

  • Drug decelerates bacterial race to antibiotic resistance

    A team of researchers at Baylor College of Medicine is gaining ground in their search for solutions to the global problem of bacterial antibiotic resistance, which was responsible for nearly 1.3 million deaths in 2019.

  • Government hikes stipend for research scholar

    The Department of Science and Technology has announced the revised stipends for PhD students and research scholars. However,research scholars are not happy with increments by the government.

    DST took to twitter to announce that Govt. has approved enhancing emoluments for JRF/SRF/RAs engaged in R&D activities whereby they will receive following fellowships /month w.e.f 01/01/2023:
    JRF - Rs 37,000
    SRF - Rs 42,000
    RA1 - Rs 58,000
    RA2 - Rs 61,000
    RA3 - Rs 63,000

  • USFDA approves First Anti-Inflammatory Drug for Cardiovascular Disease

    AGEPHA Pharma USA, LLC announced that, following a Priority Review, the U.S. Food and Drug Administration (FDA) has approved LODOCO as the first anti-inflammatory atheroprotective cardiovascular treatment demonstrated to reduce the risk of myocardial infarction (MI), stroke, coronary revascularization, and cardiovascular death in adult patients with established atherosclerotic disease or with multiple risk factors for cardiovascular disease.

  • FDA Approves New Class of Medicines to Treat Pediatric Type 2 Diabetes

    The U.S. Food and Drug Administration approved Jardiance (empagliflozin) and Synjardy (empagliflozin and metformin hydrochloride) as additions to diet and exercise to improve blood sugar control in children 10 years and older with type 2 diabetes. These approvals provide a new class of medicines taken by mouth to treat pediatric type 2 diabetes. Metformin, the only other oral therapy available for the treatment of children with type 2 diabetes, was first approved for pediatric use in 2000.

  • Belize certified malaria-free by WHO

    The World Health Organization (WHO) has certified Belize as malaria-free, following the country’s over 70 years of continued efforts to stamp out the disease.

    “WHO congratulates the people and government of Belize and their network of global and local partners for this achievement”, said Dr Tedros Adhanom Ghebreyesus, WHO Director-General. “Belize is another example of how, with the right tools and the right approach, we can dream of a malaria-free future.”

  • Omicron-specific mRNA-based Booster vaccine developed using the indigenous platform technology

    The Department of Biotechnology (DBT) has announced that the Omicron-specific mRNA-based Booster vaccine developed using the indigenous platform technology by Gennova Biopharmaceuticals Ltd. and supported under the Mission COVID Suraksha, implemented by Biotechnology Industry Research Assistance Council (BIRAC), has got a nod from the office of the Drug Control General of India (DCGI) for Emergency Use Authorization (EUA).

  • Pharmacy is an independent profession, not paramedical course : PCI

    Pharmacy council of India (PCI) notified that the pharmacy is an independent profession, and should not be linked with para-medical courses.

    There was periodic debate in the pharmacy profession that it should fall under paramedical courses or not, which was ended by an official notification from PCI.

  • Scientists identified an over-the-counter antihistamine as a treatment for multiple sclerosis

    A decade after UC San Francisco scientists identified an over-the-counter antihistamine as a treatment for multiple sclerosis, researchers have developed an approach to measure the drug’s effectiveness in repairing the brain, making it possible to also assess future therapies for the devastating disorder.

  • New Discovery Can Help Detect Brain Tumours

    Folate-based radiopharmaceuticals can be used in positron emission tomography (PET) imaging to detect folate receptors in brain tumours. The discovery of folate receptors and their exploitation potential with respect to brain tumours is a new and significant finding in the field.

Subscribe to Pharma News